Staar Surgical downgraded to Hold from Buy at Benchmark

Benchmark downgraded Staar Surgical to Hold from Buy and removed the firm’s price target after the company laid out its plan to reignite sales growth between 2024 and 2026 yesterday at an investor event. The lingering question coming into the meeting was whether the U.S. sales effort could ramp quickly enough in the next two years to reaccelerate growth as the Chinese market matures, though the plan “was not dramatically different than what was sketched out” during the Q2 call, the analyst tells investors.